Loading
Fresenius SE & Co. KGaA Stock: price and insider trades · Germany
2 insiders bought €297k of shares over the last 90 days, the latest filed 10 Sept 2026.
Fresenius SE & Co. KGaA: what insiders have been doing
Headquartered in Bad Homburg vor der Höhe, Germany, Fresenius SE & Co. KGaA belongs to the Healthcare & Pharma sector and traces its origins to 1912. Its latest reported headcount is 176,486 employees (2024). Filings by its managers are published through BaFin. The last twelve months, up to 18 October 2026, brought 10 filings signed by 7 insiders.
Only purchases show up on the open market, 10 purchases in all worth €2.0M, filed by 7 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. On the buying side, the filings list 7 senior executives among the declarants. Biggest ticket of the year: €400k, bought by Sen, Michael and made public on 1 April 2026 (0.0015% of market cap).
In the case of 6 purchases, another manager of the company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last purchase on record was published on 10 September 2026, which is 37 days ago. Between a trade and the moment it shows up on BaFin, the median delay is 1 day. Under the Market Abuse Regulation, managers have three business days to notify their trades.
With 10 filings in twelve months, the company is more active than the median of 5 filings across the 287 companies we follow on the same exchange. Our records for Fresenius SE & Co. KGaA go back to 2026, with 10 purchases and no sales on the open market in total.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Source: insider filings from BaFin. Past trades are no guide to future returns.
Insider Decl.
10
Thresholds
n/a
Buy Volume
€2M
10 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleMichael Sen6 buys
Sara Hennicken3 buys
Pierluigi Antonelli1 buy
Robert Möller1 buy
Analyst consensus: bullish or bearish?
Analysts rate Fresenius SE & Co. KGaA Strong Buy (bullish), based on 14 analysts. Average price target: €55.66.
Fundamental score
Ranked 11,165 of 24,148 companies
53.5
score / 100
Value62
Quality45
FCF yld4.4%
Earn yld5.1%
EV/EBITDA9.8x
ROE8.3%
Gross mgn25%
Net mgn5.5%
Debt/EBITDA3.2x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
€43.86
Analyst consensus
14 analystsStrong buy
€50.00Target €55.66(+27%)€63.50
Income statement
Revenue€22.9B
Gross profit€5.7B25% margin
EBITDA€3.8B16% margin
Net income€1.3B6.5% margin
Valuation
PER (trailing)15.7x
PER (forward)11.1x
P/Book1.3x
Beta0.82
Balance sheet & cash
Market cap€24.7B
Total debt€11.9B
Free Cash Flow€1.1B
Debt / Equity56%
Profitability & ownership
ROE8.3%
ROA3.4%
% insiders27.0%
% institutions44.0%
Last declaration on 10 September 2026
Declarations10 total
2,249.992 shares@ €44.550.0004% mcap28.6% of flowShareXetraISIN DE000FRE5EN2BAFIN:40001016-27303c0a87d0
Canonical exit: 8 Dec 2026 (T+90)
4,612.211 shares@ €42.700.0008% mcap15.3% of flowShareXetraISIN DE000FRE5EN2BAFIN:40001016-0444710650e9
Canonical exit: 6 Dec 2026 (T+90)
5,367.564 shares@ €36.730.0007% mcap15.3% of flowShareXetraISIN DE0005785604BAFIN:40001016-af05e426e2db
Canonical exit: 26 Aug 2026 (T+90)
7,499.926 shares@ €40.340.0011% mcap23.4% of flowShareXETRAISIN DE0005785604BAFIN:40001016-902471c26383
Canonical exit: 5 Aug 2026 (T+90)
9,042.543 shares@ €44.240.0015% mcap31.0% of flowShareXETRAISIN DE0005785604BAFIN:40001016-de62c281f8fd
Canonical exit: 29 Jun 2026 (T+90)
2,542.854 shares@ €44.240.0004% mcap100.0% of flowShareXETRAISIN DE0005785604BAFIN:40001016-ada3ba8a8961
Canonical exit: 29 Jun 2026 (T+90)
3,390.835 shares@ €44.240.0005% mcap42.8% of flowShareXETRAISIN DE0005785604BAFIN:40001016-a9ec626ff198
Canonical exit: 29 Jun 2026 (T+90)
4,814.714 shares@ €44.240.0008% mcap100.0% of flowShareXETRAISIN DE0005785604BAFIN:40001016-d01df4c4c02f
Canonical exit: 29 Jun 2026 (T+90)
2,147.158 shares@ €46.540.0004% mcap28.5% of flowShareXETRAISIN DE0005785604BAFIN:40001016-760c80f09f87
Canonical exit: 10 Jun 2026 (T+90)
4,129.77 shares@ €47.110.0007% mcap15.1% of flowShareXETRAISIN DE0005785604BAFIN:40001016
Canonical exit: 3 Jun 2026 (T+90)
10 of 10 declarations
About Fresenius SE & Co. KGaA
Fresenius SE & Co. KGaA is an international healthcare group listed on Xetra/Frankfurt (DAX/MDAX/SDAX), in Germany, and is widely regarded as one of Europe’s leading providers of essential healthcare products and services. The company was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, near Frankfurt. Fresenius today operates as a therapy-focused healthcare group serving critically and chronically ill patients, combining industrial healthcare products with hospital operations.
The group’s business model is built primarily around two operating pillars: Fresenius Kabi and Fresenius Helios. Fresenius Kabi develops and markets injectable generics, biosimilars, clinical nutrition products, and technologies and services related to infusion therapy, anesthesia, and medical devices. Fresenius Helios operates hospitals and clinics, mainly in Germany and Spain, under the Helios and Quirónsalud brands. This structure gives Fresenius a balanced exposure to both healthcare manufacturing and hospital care, with a relatively defensive end-market profile.
Read moreShow less
From a competitive standpoint, Fresenius is positioned as an integrated healthcare solutions provider, with reach across pharmaceutical supply, clinical nutrition, and hospital treatment pathways. That integration is strategically valuable in segments such as sterile injectables, biosimilars, and clinical nutrition, where manufacturing scale, reliability of supply, and regulatory execution matter materially. The group also emphasizes a “local for local” production approach, supported by a manufacturing network spanning Europe, the United States, and Asia.
Recent developments show Fresenius continuing to execute its #FutureFresenius transformation agenda. In 2025, management highlighted sustained organic growth, raised full-year guidance, and ongoing progress across key growth areas. The latest company updates also point to continued momentum in biosimilars and pharmaceuticals, improved operating performance, and a stronger balance-sheet profile. For investors, Fresenius remains a notable healthcare name with defensive characteristics, improving margin potential, and a visible medium-term value-creation story anchored in operational discipline and portfolio focus.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
